The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in
Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications …

This Focus Issue on thrombosis and antithrombotic treatment contains the State of the Art
Review article 'Towards personalized antithrombotic management with drugs and devices …

Bleeding events in patients with acute coronary syndrome (ACS) are a risk factor for adverse
outcomes, including mortality. We investigated the association of growth differentiation factor …

Considering that there is no definite conclusion on the efficacy and safety of switching from
potent P2Y 12 inhibitors to clopidogrel, we conducted a systematic review and meta …

Background The net clinical benefit of antithrombotic therapy (ATT) reflects the concomitant
effects of bleeding and ischemic events. Objectives We sought to assess the overall effect of …

Background Current evidence supports the efficacy of prolonged dual antiplatelet treatment
(DAPT) for patients at high-ischemic risk and low bleeding risk as well as the efficacy and …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended
following percutaneous coronary intervention (PCI) to reduce the risk for major adverse …

The standard course of 12-month dual antiplatelet therapy (DAPT) with aspirin plus a potent
P2Y12 inhibitor (ie, prasugrel or ticagrelor) is established to be an effective strategy in …

Sudden cardiac arrest (SCA) is a challenging situation, particularly when it happens out of
hospital. 1–4 This Focus Issue on arrhythmias contains the contribution entitled 'Association …

Background: Dual antiplatelet therapy (DAPT) with potent P2Y12 inhibitor is the cornerstone
of acute coronary syndrome (ACS) management. Balancing the effects of different strategies …